Abstract
Ovarian cancer remains one of the most fatal pathologies among women around the world due to late diagnosis on the advanced stages of the tumor process. Serous ovarian carcinomas (SOC) often recur, which worsens the prognosis for patients’ recovery and survival. The identification of prognostic clinical and morphological factors that predict the appearance of recurrence remains an urgent problem.
 The aim of the research was studying relationships between the phenomenon of epithelial-mesenchymal transformation (EMT) and the expression of surface cancer stem cells (CSCS) markers to identify recurrence predictors among women with low grade serous ovarian carcinomas (LGSC).
 The material were paraffin blocks and slides of 43 patients with LGSC I-IV FIGO stage. The study included 30 cancers without recurrence and 13 tumors with it within 24 months. The expression of E-cadherin, Vimentin, CD44 and CD117 was studied using immunohistochemical (IHC) method.
 Results. Development of recurrence is typical for women with stage III-IV (p=0,01), the expression of Vimentin at level 51–100 % (p=0,001) and E-cadherin at 10–50 % (p=0.04). CD44 was expressed in 51.16 % of tumors and level didn`t depend on age, recurrence, but depended on disease stage (p=0.001). Recurrent LGSCs are characterized by the expression of CD117> 10 % (p=0.0001), its direct correlation with the stage (p=0.0001) and the recurrence (p=0.0001). A direct relationship was found between the CD117 and Vimentin expression.
 Conclusions. Prognostic markers of recurrence should be considered stage III-IV, levels of Vimentin 51–100 %, E-cadherin 10-50 % and CD117> 10 %. A correlation between CD117 and Vimentin expression indicates the commonality of EMT and CSCS in progression and recur. CD44 has no independent prognostic role.
Highlights
Ovarian cancer is one of the most fatal female reproductive system cancers [1]
Menopause occurred in 23.08 % (3/13) of patients from the group of recurrent low grade serous ovarian carcinomas (LGSC), in the group of LGSCs without recurrence menopause was recorded in 13.33 % (4/30) cases
For LGSCs without recurrence are typical initial (I–II) stages of the disease with no terminal (IV) stage, while recurrent LGSCs are characterized by disease stage III-IV with no cases diagnosed in stage I (χ2=20.95, p=0.0051) and a significant decreasing of cases diagnosed in stage II (χ2=14.37, p=0.0059) (Table 1)
Summary
Ovarian cancer is one of the most fatal female reproductive system cancers [1]. Based on data provided by the WHO, 225,500 casesPROGNOSIS ROLE OF EPITELIAL-MEZENCHIMAL TRANSFORMATION MARKERS AND SURFACE STEM TUMOR CELLS IN THE RECCURENCE OF SEROUS LOW GRADE OVARI-currence and without it, as well as the relationship between the expression of CSCS and EMT markers to identify possible predictors of recurrence in patients.of ovarian cancer are diagnosedAN CARCINOMAS worldwide each year and 140,200 deaths are reported. Ovarian cancer is one of the most fatal female reproductive system cancers [1]. Based on data provided by the WHO, 225,500 cases. PROGNOSIS ROLE OF EPITELIAL-MEZENCHIMAL TRANSFORMATION MARKERS AND SURFACE STEM TUMOR CELLS IN THE RECCURENCE OF SEROUS LOW GRADE OVARI-. Currence and without it, as well as the relationship between the expression of CSCS and EMT markers to identify possible predictors of recurrence in patients. AN CARCINOMAS worldwide each year and 140,200 deaths are reported. Among the female population, according to world statistics, ovarian cancer ranks 7th in the structure of morbidity and 8th in the structure of
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
